98%
921
2 minutes
20
Purpose: To compare cervical cancer screening prevalence between urban and rural women aged 30-49 years in three sub-Saharan African countries chosen by their country-specific screening strategy (Burkina Faso, which has a systematic population-based cervical cancer screening programme in place; Tanzania, where opportunistic screening options only are implemented; and Ghana, which has implemented neither one).
Methods: We used the most recent Demographic and Health Surveys data from Burkina Faso, Ghana and Tanzania. We restricted our analysis to women aged 30-49 eligible for cervical cancer screening and categorised them by their place of residence as urban or rural. We calculated screening proportions using country-specific survey weights to estimate the absolute prevalence difference in cervical cancer screening between urban/rural residents.
Results: Rural participants represented 69.5% in Burkina Faso, 64.6% in Tanzania and 42.8% in Ghana. Burkina Faso women reported higher cervical cancer screening prevalence at 19.9%, and Ghana participants reported the lowest at 7.4%. Compared with urban participants, rural women screened less across countries, with an absolute prevalence difference in screening wider in Tanzania at 13.1% (95% CI 10.6% to 15.7%), followed by Burkina Faso at 11.1% (95% CI 7.7% to 14.6%) and narrower in Ghana at 5.9% (95% CI 4.1% to 7.7%).
Conclusion: We found a consistently low screening uptake and a screening prevalence gap disfavouring rural women from these three sub-Saharan African countries, with the narrowest urban/rural gap in Ghana and the widest in Tanzania, which has a large opportunistic cervical cancer screening programme. Our findings offer no indication of a potential benefit of having a systematic screening programme as a tool that can mitigate the screening gap between urban and rural populations. Further screening uptake studies, including more countries, are needed on this topic, which should account for the existing country-specific non-screening related factors in the healthcare system that may influence cervical cancer screening uptake.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12406890 | PMC |
http://dx.doi.org/10.1136/bmjgh-2024-018634 | DOI Listing |
Int J Cancer
September 2025
Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Cervical cancer remains a significant public health issue, ranking as the fourth most common cancer in women globally. In the Netherlands, cervical cancer incidence declined steadily from 1989 to 2001 but increased between 2001 and 2007. This study updates trends in cervical cancer incidence from 1989 to 2023 in the Netherlands and evaluates the impact of screening practices and participation rates in the national population-based screening program.
View Article and Find Full Text PDFCochrane Database Syst Rev
September 2025
Institute for Evidence in Medicine, Medical Center - University of Freiburg / Medical Faculty - University of Freiburg, Freiburg, Germany.
Rationale: Cervical cancer is the fourth most common cancer affecting women worldwide, caused by persistent infection with oncogenic human papillomavirus (HPV) types. While HPV infections usually resolve spontaneously, persistent infections with high-risk HPV types can progress to premalignant glandular or - mostly - squamous intraepithelial lesions, usually classified in cervical intraepithelial neoplasia (CIN). Women with CIN 2 and CIN 3 (i.
View Article and Find Full Text PDFRep Pract Oncol Radiother
August 2025
University Teaching Department, Chhattisgarh Swami Vivekanand Technical University, Bhilai, India.
Cervical cancer continues to pose a significant global health challenge, highlighting the urgent need for accurate and efficient diagnostic techniques. Recent progress in deep learning has demonstrated considerable potential in improving the detection and classification of cervical cancer. This review presents a thorough analysis of deep learning methods utilized for cervical cancer diagnosis, with an emphasis on critical approaches, evaluation metrics, and the ongoing challenges faced in the field.
View Article and Find Full Text PDFRep Pract Oncol Radiother
August 2025
University Teaching Department, Chhattisgarh Swami Vivekanand Technical University, Bhilai, India.
Background: Cervical cancer (CC) is a leading cause of cancer-related deaths worldwide, emphasizing the need for accurate and efficient diagnostic tools. Traditional methods of cervical cell classification are time-consuming and susceptible to human error, highlighting the need for automated solutions.
Materials And Methods: This study introduces the modified hierarchical deep feature fusion (HDFF) method for cervical cell classification using the SIPaKMeD and Herlev datasets.
Front Oncol
August 2025
Hunan Cancer Hospital, The Affiliated Cancer Hospital, Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
Tislelizumab, an anti-PD-1 monoclonal antibody, is associated with immune-related hepatitis in 1.8% of cases, but reports of acute liver failure (ALF) remain exceedingly rare. We present a case of fulminant hepatitis and ALF following Tislelizumab therapy in a 55-year-old woman with locally advanced cervical adenocarcinoma.
View Article and Find Full Text PDF